Influence of carbenoxolone on the anticonvulsant efficacy of conventional antiepileptic drugs against audiogenic seizures in DBA/2 mice

• Published in: European journal of pharmacology Vol. 484; no. 1; pp. 49 - 56
• Main Authors: Gareri, Pietro, Condorelli, Daniele, Belluardo, Natale, Gratteri, Santo, Ferreri, Guido, Donato Di Paola, Eugenio, De Sarro, Angela, De Sarro, Giovambattista
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 19.01.2004; Elsevier
• Subjects: Acoustic Stimulation - adverse effects; Acoustic Stimulation - methods; Animals; Anticonvulsant potency; Anticonvulsants - pharmacokinetics; Anticonvulsants - therapeutic use; Antiepileptic drug; Audiogenic seizure; Biological and medical sciences; Carbamazepine; Carbenoxolone; Carbenoxolone - pharmacokinetics; Carbenoxolone - therapeutic use; DBA/2; Drug Synergism; Epilepsy; Epilepsy, Reflex - blood; Epilepsy, Reflex - drug therapy; Felbamate; Gap junction; Medical sciences; Mice; Mice, Inbred DBA; Motor Activity - drug effects; Motor Activity - physiology; mouse; Pharmacology. Drug treatments; Phenytoin; Valproate; Antiepileptic drug; Carbenoxolone; Felbamate; Epilepsy; Anticonvulsant potency; DBA/2; Gap junction; Carbamazepine; Phenytoin; Valproate; Audiogenic seizure; Drug; Nervous system diseases; Rodentia; Antiinflammatory agent; Anticonvulsant; Cerebral disorder; Audiogenic epilepsy; Vertebrata; Mammalia; Mouse; Animal; Central nervous system disease

Carbenoxolone, the succinyl ester of glycyrrhetinic acid, is an inhibitor of 11β-hydroxy steroid dehydrogenase and gap junctional intercellular communication. It is currently used in clinical treatment of ulcer diseases. Systemic administration of carbenoxolone (1–40 mg/kg, intraperitoneally (i.p.))...